Company: ENTXW
Filing Date: 2025-07-28
Form Type: 8-K
Source: 0001178913-25-002484
Chunk: 2

Company: Entera Bio Ltd.
Filing Date: 2025-07-28
Form: 8-K
Item: Item 9.01
Chunk 2
---
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit      Description                                                                                                                                                   
   Number                                                                                                                                                                    
     99.1      Press Release, dated                                                                                                                                          
               July 28, 2025, announcing the FDA’s Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis.  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      104      Cover Page Interactive Data File (embedded within the Inline XBRL document)                                                                                   

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.

                                    ENTERA BIO LTD.                 
  Date: July 28, 2025      By:      /s/ Miranda Toledano            
                                    Name: Miranda Toledano